Comparison 1. Mepolizumab 100 mg versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 Rate of moderate or severe exacerbations	2		Rate Ratio (IV, Fixed, 95% CI)	Subtotals only
1.1.1 Eosinophilic phenotype	2	911	Rate Ratio (IV, Fixed, 95% CI)	0.81 [0.71, 0.93]
1.1.2 All participants	2	1285	Rate Ratio (IV, Fixed, 95% CI)	0.92 [0.82, 1.03]
1.2 Time to first moderate or severe exacerbation	2		Hazard Ratio (IV, Fixed, 95% CI)	Subtotals only
1.2.1 Eosinophilic phenotype	2	981	Hazard Ratio (IV, Fixed, 95% CI)	0.78 [0.66, 0.92]
1.2.2 All participants	2	1285	Hazard Ratio (IV, Fixed, 95% CI)	0.87 [0.75, 1.00]
1.3 Rate of exacerbations with ED visit or hospitalisation	2		Rate Ratio (IV, Fixed, 95% CI)	Subtotals only
1.3.1 Eosinophilic phenotype	2	911	Rate Ratio (IV, Fixed, 95% CI)	0.90 [0.65, 1.24]
1.3.2 All participants	2	1285	Rate Ratio (IV, Fixed, 95% CI)	0.94 [0.72, 1.22]
1.4 Serious adverse events	2	1285	Odds Ratio (M‐H, Fixed, 95% CI)	0.82 [0.65, 1.05]
1.5 Health‐related quality of life: change in SGRQ total score	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
1.5.1 Eosinophilic phenotype	2	911	Mean Difference (IV, Fixed, 95% CI)	‐0.90 [‐2.91, 1.10]
1.5.2 All participants	2	1285	Mean Difference (IV, Fixed, 95% CI)	‐0.30 [‐2.00, 1.41]
1.6 COPD Assessment Test: change in CAT score	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
1.6.1 Eosinophilic phenotype	2	911	Mean Difference (IV, Fixed, 95% CI)	‐0.95 [‐1.80, ‐0.10]
1.6.2 All participants	2	1285	Mean Difference (IV, Fixed, 95% CI)	‐0.78 [‐1.50, ‐0.06]
1.7 Mortality	2	1285	Odds Ratio (M‐H, Fixed, 95% CI)	0.77 [0.42, 1.39]
1.8 Adverse events	2	1285	Odds Ratio (M‐H, Fixed, 95% CI)	0.97 [0.77, 1.21]